Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Indoleamine 2,3-dioxygenase and immune changes under antidepressive treatment in major depression in females.

Zoga M, Oulis P, Chatzipanagiotou S, Masdrakis VG, Pliatsika P, Boufidou F, Foteli S, Soldatos CR, Nikolaou C, Papageorgiou C.

In Vivo. 2014 Jul-Aug;28(4):633-8.

PMID:
24982234
2.

Baseline Heartbeat Perception Accuracy and Short-Term Outcome of Brief Cognitive-Behaviour Therapy for Panic Disorder with Agoraphobia.

Masdrakis VG, Legaki EM, Vaidakis N, Ploumpidis D, Soldatos CR, Papageorgiou C, Papadimitriou GN, Oulis P.

Behav Cogn Psychother. 2013 Dec 13:1-10. [Epub ahead of print]

PMID:
24330918
3.

On the differential diagnosis of anxious from nonanxious major depression by means of the Hamilton Scales.

Konstantakopoulos G, Masdrakis VG, Markianos M, Oulis P.

ScientificWorldJournal. 2013 Oct 27;2013:294516. doi: 10.1155/2013/294516. eCollection 2013.

4.

Testosterone and dehydroepiandrosterone sulfate in female anxious and non-anxious major depression.

Oulis P, Masdrakis VG, Markianos M.

Int J Psychiatry Clin Pract. 2014 Jan;18(1):21-4. doi: 10.3109/13651501.2013.845222. Epub 2013 Oct 28.

PMID:
24047428
5.

Pregabalin for the treatment of generalized anxiety disorder: an update.

Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R.

Neuropsychiatr Dis Treat. 2013;9:883-92. doi: 10.2147/NDT.S36453. Epub 2013 Jun 24.

6.

Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants.

Baldwin DS, Palazzo MC, Masdrakis VG.

Depress Res Treat. 2013;2013:256841. doi: 10.1155/2013/256841. Epub 2013 Feb 4.

7.

Pharmacological treatment of social anxiety disorder.

Masdrakis VG, Turic D, Baldwin DS.

Mod Trends Pharmacopsychiatri. 2013;29:144-53. doi: 10.1159/000351960. Epub 2013 Sep 20. Review.

PMID:
25225024
8.

Pregabalin in zolpidem dependence and withdrawal.

Oulis P, Nakkas G, Masdrakis VG.

Clin Neuropharmacol. 2011 Mar-Apr;34(2):90-1. doi: 10.1097/WNF.0b013e31820a3b5a.

PMID:
21407000
9.

Cardiac safety of the electroconvulsive therapy-paliperidone combination: a preliminary study.

Masdrakis VG, Tzanoulinos G, Markatou M, Oulis P.

Gen Hosp Psychiatry. 2011 Jan-Feb;33(1):83.e9-10. doi: 10.1016/j.genhosppsych.2010.09.012. Epub 2010 Oct 29.

PMID:
21353140
10.

Corrected QT interval changes during electroconvulsive therapy-antidepressants-atypical antipsychotics coadministration: safety issues.

Oulis P, Florakis A, Markatou M, Tzanoulinos G, Masdrakis VG.

J ECT. 2011 Mar;27(1):e4-6. doi: 10.1097/YCT.0b013e3181d77632.

PMID:
21343709
11.

Lamotrigine administration in panic disorder with agoraphobia.

Masdrakis VG, Papadimitriou GN, Oulis P.

Clin Neuropharmacol. 2010 May;33(3):126-8. doi: 10.1097/WNF.0b013e3181d4c1f6.

PMID:
20502131
12.

Safety of the electroconvulsive therapy-ziprasidone combination.

Masdrakis VG, Florakis A, Tzanoulinos G, Markatou M, Oulis P.

J ECT. 2010 Jun;26(2):139-42. doi: 10.1097/YCT.0b013e3181c1880e.

PMID:
20386116
13.

Bupropion-induced sleepwalking.

Oulis P, Kokras N, Papadimitriou GN, Masdrakis VG.

J Clin Psychopharmacol. 2010 Feb;30(1):83-4. doi: 10.1097/JCP.0b013e3181c9c8a2. No abstract available.

PMID:
20075658
14.

Adjunctive low-dose amisulpride in motor conversion disorder.

Oulis P, Kokras N, Papadimitriou GN, Masdrakis VG.

Clin Neuropharmacol. 2009 Nov-Dec;32(6):342-3. doi: 10.1097/WNF.0b013e3181b20144.

PMID:
19952874
15.

Reversal of increased arterial stiffness in severely depressed women after 6-week antidepressant treatment.

Oulis P, Kouzoupis A, Kyrkou K, Masdrakis VG, Georgiopoulos G, Karapoulios E, Georgiou S, Karakatsanis NA, Lykka M, Papadimitriou GN, Papamichael C, Stamatelopoulos K.

J Affect Disord. 2010 Apr;122(1-2):164-6. doi: 10.1016/j.jad.2009.08.003. Epub 2009 Sep 3.

PMID:
19729203
16.

Fluvoxamine in the treatment of corticosteroid-induced obsessive-compulsive disorder.

Oulis P, Masdrakis VG, Florakis A, Papadimitriou GN.

Clin Neuropharmacol. 2009 May-Jun;32(3):176-7. doi: 10.1097/WNF.0b013e31817c41c0. No abstract available.

PMID:
19483493
17.

Quetiapine-induced dose-dependent hypersalivation in mania.

Oulis P, Masdrakis VG, Karakatsanis NA, Kouzoupis AV, Papadimitriou GN.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):56-7. doi: 10.1097/WNF.0b013e3181634e8e. No abstract available.

PMID:
19471187
18.

For publication: Tiagabine in the discontinuation of long-term benzodiazepine use.

Oulis P, Masdrakis VG, Karapoulios E, Karakatsanis NA, Kouzoupis AV, Papadimitriou GN.

Psychiatry Clin Neurosci. 2009 Feb;63(1):122. doi: 10.1111/j.1440-1819.2008.01890.x. No abstract available.

PMID:
19154218
19.

Reversible tremor and myoclonus associated with topiramate-fluvoxamine coadministration.

Oulis P, Potagas C, Masdrakis VG, Thomopoulos Y, Kouzoupis AV, Soldatos CR.

Clin Neuropharmacol. 2008 Nov-Dec;31(6):366-7. doi: 10.1097/WNF.0b013e31815ce4c2.

PMID:
19050415
20.

Caffeine challenge and breath-holding duration in patients with panic disorder.

Masdrakis VG, Markianos M, Vaidakis N, Papakostas YG, Oulis P.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):41-4. doi: 10.1016/j.pnpbp.2008.10.002. Epub 2008 Oct 9.

PMID:
18930777
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk